XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Depreciation expense $ 9,278 $ 892 $ 16,910 $ 10,417  
Research and Development Cost 566,568 271,964 1,101,715 627,869  
Cash and cash equivalents 5,083,482   5,083,482   $ 10,445,404
Revenues from sale of treatability services 27,048 0 46,230 8,000  
Revenues from sales $ 9,773 $ 49,863 305,869 $ 843,321  
Inventory allowance     50,000   0
Contract loss provision     $ 600,000   $ 500,000
Share based description     cumulative adjustment of approximately $55,000 in the quarter ended December 31, 2023 to reduce its forfeiture rate estimate to approximately 5% of the total stock-based compensation recognized during the year    
Options [Member]          
Antidilutive Excluded from Computation of Earnings Per Share, Amount     15,999,370 12,855,467  
Unvested Restricted Stock [Member]          
Antidilutive Excluded from Computation of Earnings Per Share, Amount     2,962,000    
Warrants [Member]          
Antidilutive Excluded from Computation of Earnings Per Share, Amount     1,235,000 1,235,000  
One Customer [Member] | Revenue [Member]          
Concentrations of Credit Risk     87.00% 90.00%